Frontiers in Immunology (Mar 2022)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies

  • Takuya Tada,
  • Hao Zhou,
  • Marie I. Samanovic,
  • Marie I. Samanovic,
  • Belinda M. Dcosta,
  • Amber Cornelius,
  • Amber Cornelius,
  • Ramin S. Herati,
  • Ramin S. Herati,
  • Mark J. Mulligan,
  • Mark J. Mulligan,
  • Mark J. Mulligan,
  • Nathaniel R. Landau

DOI
https://doi.org/10.3389/fimmu.2022.797589
Journal volume & issue
Vol. 13

Abstract

Read online

The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine effectiveness. Here, neutralizing antibody titers elicited by mRNA-based and adenoviral vector-based vaccines against variant pseudotyped viruses were measured. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals had less neutralizing titer (IC50 <50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest a potential benefit by second immunization following Ad26.COV2.S to increase protection from current and future variants.

Keywords